At the beginning of 2026, Zhejiang Tianyuan Biotechnology Co., Ltd. announced momentous news: the company has achieved a series of milestone accomplishments in the field of iPSC (induced Pluripotent Stem Cell) research, with multiple core technologies reaching internationally leading levels.

      Solving the "Heart" Challenge: 90% Recovery Rate Redefines Transplant Safety Standards

      The heart is the engine of life. However, diseases such as myocardial infarction and heart failure ruthlessly claim countless lives every year. Traditional treatments often only delay disease progression but cannot truly repair damaged myocardium. iPSCs, hailed as "universal cells," have brought hope for the complete cure of these conditions.

      However, turning this vision into reality faces significant technical barriers. Among them, the risk of post-transplant arrhythmia and the extremely low cell recovery rate after cryopreservation have been two "world-class" challenges. Today, Dr. Chen Junjie, Technical Director of Tianyuan Biotech, has led his team through countless explorations and breakthroughs to deliver a perfect solution.

      Breakthrough 1: Resolving Post-Transplant Arrhythmia

      Tianyuan Biotech has successfully overcome the challenge where cardiomyocytes prepared by traditional methods easily induce arrhythmia after clinical ventricular transplantation. Cardiomyocytes produced via conventional methods are often contaminated with pacemaker cells and lack sufficient maturity, causing asynchronous electrical signaling with the patient's native heart. Through an optimized cardiomyocyte differentiation protocol developed by Dr. Chen’s team, non-target pacemaker cell generation is thoroughly suppressed via precise signal pathway regulation, while left ventricular cardiomyocyte maturation is accelerated to reduce autonomous pacing risks. This means transplanted cells can seamlessly integrate into the recipient heart's electrophysiological rhythm, fundamentally eliminating the risk of fatal arrhythmias and significantly enhancing clinical safety.

      Breakthrough 2: Redefining "Industrial Efficiency": Leap from 30% to 90% Cell Recovery Rate

      The commercialization of cell therapies hinges on CMC (Chemistry, Manufacturing, and Controls). For years, mature cardiomyocytes suffered losses of up to 70%-80% during cryopreservation and thawing; high production costs and logistical difficulties limited their widespread adoption. Abandoning the traditional path of cryopreserving mature cells, the Tianyuan team achieved efficient cryopreservation of ventricular progenitor cells through a proprietary cryoprotection system. The recovery rate has surged from an industry average of 30% to over 90%. This not only resolves major logistical hurdles—making scalable production and storage of "off-the-shelf" cell drugs possible—but also drastically reduces end-treatment costs, building a formidable cost moat.

      Leading in "Organoids": Dual Breakthroughs in Pacemaker Cells and Large Animal Trials

      Beyond myocardial repair, Tianyuan Biotech demonstrates globally leading R&D depth in cardiac electrophysiological reconstruction.

      Pacemaker Cell-Derived Organoid Research: The team has successfully generated highly biomimetic sinoatrial node organoids using iPSCs. These organoids can sense physiological signals and generate rhythmic impulses, holding promise to replace traditional electronic pacemakers and offer bradycardia patients a lifelong solution free from battery replacements or foreign body rejection.

      Cardiomyocyte Differentiation Project: Tianyuan Biotech’s core project has now fully entered the large animal testing phase. As the most critical validation step before Investigational New Drug (IND) filing, preliminary data demonstrate exceptional tissue integration and improved cardiac function, bringing the therapy one step closer to benefiting patients.

      Powerful Synergy: A Fusion of In-House Teams and Global Wisdom

      Tianyuan Biotech’s pioneering breakthroughs are no accident. They result from the tireless dedication of the company’s in-house scientists, collaborative support from top international experts, and robust backing from China’s strong technological infrastructure.

      Leveraging national and regional platforms—including the National Health Commission (NHC) Research Institute, the National Stem Cell Translational Resource Bank, and Ningbo University School of Medicine—Tianyuan Biotech has built an innovation ecosystem characterized by "enterprise-led, platform-supported, multi-party collaboration." This unique advantage allows Tianyuan Biotech to stand on the shoulders of giants, seeing further and running faster.

      From "Impossible" to "Universal Benefit": Technology for Good, Benefiting Humanity

      As a prime example of new quality productive forces, Tianyuan Biotech’s iPSC breakthroughs hold profound strategic significance for domestic biopharmaceutical development. While these sophisticated scientific terms and experimental data may seem distant from everyday life, they embody humanity’s fervent desire to combat disease and pursue health.

      This aligns perfectly with Tianyuan Biotech’s enduring mission: Turning the impossible into possible, the possible into value, and value into universal benefit!

      Through concrete actions, Tianyuan Biotech is making this vision a reality. We firmly believe that one day, these once-"unattainable" scientific breakthroughs will become a warm force safeguarding life, entering ordinary households and bringing higher-quality life experiences and health benefits to all mankind.

      Life begins with cells and ends with cells, but science enables life to endure. Tianyuan Biotech remains steadfast on this journey.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell research and development, manufacturing, operations, and services. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Bank, an iPS Seed Cell Bank, and a Tumor Cell Bank. It is also a participating unit in formulating the group standard for immune function assessment methods under the National Health Commission (NHC). Furthermore, Tianyuan Biotech has co-established the Joint Laboratory for Metabolic Immune Monitoring with the NHC Research Institute, and serves as key research service platforms such as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Transformation Center of the NHC Research Institute.